Latest Commercial Execution News

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

BPH Global has secured a $1 million strategic placement to accelerate growth of its Indonesian seaweed trading operations, backed by record sales and robust infrastructure. This capital injection aims to boost trading volumes and pave the way for higher-margin revenue streams.

Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.

AVADA Group Limited reported a robust 24% increase in cash receipts for Q2 FY26, driven by strong sales and strategic leadership changes, while expanding its trade finance facility to support ongoing growth.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

Provaris Energy has made significant strides in hydrogen and liquid carbon dioxide storage technologies, reinforcing key partnerships and securing funding to meet critical 2026 milestones.

HITIQ has made significant strides in expanding its concussion management technology, PROTEQT©, into North America and Australian retail, backed by strong research partnerships and a successful capital raise.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.